Prostatic Urethral Lift: What to Expect From the Procedure

The prostatic urethral lift is a minimally invasive procedure that uses small permanent implants to physically hold open the compressed urethra inside an enlarged prostate, relieving urinary symptoms without cutting, heating, or removing any tissue. Most men go home the same day, notice improved urinary flow within days to weeks, and face a recovery measured in days rather than the weeks typical of traditional prostate surgery. The trade-off is that symptom relief, while durable for many, is somewhat less dramatic than what conventional surgery delivers, and a meaningful percentage of men eventually need a second procedure.

How the Implants Actually Work

An enlarged prostate squeezes the urethra from both sides, making it hard to start or maintain a urine stream. The prostatic urethral lift addresses this mechanically. A surgeon inserts a delivery device through the urethra under cystoscopic guidance and deploys small implants that compress the prostate lobes outward. Each implant consists of a small stainless steel tab on the urethral surface connected by a monofilament suture to an anchor on the outer capsule of the prostate. The inner tissue of the prostate is softer and more compressible than the tough outer capsule, so the tension on the suture pushes the lobes apart and immediately widens the urethral channel.¹ No tissue is burned, vaporized, or excised. The procedure typically requires four to six implants placed along the length of the prostatic urethra, from the bladder neck down to the apex.²

Because the lift is purely mechanical, it starts working right away. There is no waiting for tissue to shrink, scar, or be reabsorbed. The urethra is wider the moment the implants are deployed. This is a fundamental difference from heat-based or ablative alternatives, where the body needs weeks to clear away the treated tissue before the channel opens up.

What Happens on Procedure Day

The prostatic urethral lift can be performed in an office, ambulatory surgery center, or hospital. One of its selling points is flexibility with anesthesia. A systematic review of the literature on local anesthesia for this procedure found that techniques such as topical lidocaine instillation and prostatic nerve blocks provided satisfactory pain control with high patient tolerability. Pain scores across studies ranged widely, from mild to moderate on standard pain scales.³ Some men receive light sedation on top of local anesthesia, while others undergo the procedure with local anesthetic alone. The choice often depends on patient preference, prostate size, and the clinical setting.

The procedure itself usually takes under an hour. A rigid cystoscope is passed through the urethra so the surgeon can visualize the prostate lobes and the degree of obstruction. The delivery device is then used to deploy each implant one at a time. Men may feel pressure or brief discomfort with each deployment, but most tolerate it well. Afterward, the scope is withdrawn.

In a large real-world analysis of nearly 3,000 men in England, about 93% were catheter-free at discharge, meaning they walked out without a urinary catheter in place.⁴ That same study found roughly 93% remained catheter-free at 30 days. A small percentage of men, particularly those who already had a catheter before surgery due to urinary retention, do need one temporarily afterward.

What Recovery Looks Like

Recovery is one of the main reasons men choose this procedure over conventional surgery. Most men return to normal activities within a few days. There is no incision, no packing, and no prolonged catheter use. That said, the first couple of weeks are not entirely comfortable.

The most common side effects in the early postoperative period include blood in the urine, burning or discomfort with urination, urinary urgency, and pelvic pain. In one prospective study, about 80% of men experienced some transient blood in the urine lasting a median of four days, roughly three-quarters reported burning with urination, about a quarter had temporary incontinence, and about a fifth had pelvic pain.⁵ These symptoms are considered mild to moderate and typically resolve within two to four weeks.⁶

Serious complications are uncommon. A review of reports submitted to the FDA’s adverse event database identified rare late complications including implant encrustation (mineral buildup on the implant), urethral stricture formation, and cases where an incorrectly placed implant caused persistent pain or new-onset incontinence, sometimes requiring implant removal.⁷ These events are rare enough that they show up as individual case reports rather than as common percentages in clinical trials, but they are worth knowing about.

How Much Symptom Relief to Expect

The standard way urologists measure urinary symptom severity is the International Prostate Symptom Score, a seven-question survey where higher scores mean worse symptoms. A score above 20 generally means severe symptoms. The pivotal clinical trial for this procedure, called the L.I.F.T. study, showed that symptom scores remained meaningfully improved out to five years, with an average improvement of about eight points compared to baseline. Urinary flow rate and quality of life also stayed improved throughout that period.⁸

A real-world longitudinal cohort study found even more encouraging numbers in practice. Median symptom scores dropped from 22 at baseline to 9 within three months, then continued improving to a median of 5 between 12 and 24 months. Urinary flow rate increased by more than half on average.⁹ For men who crossed over from the sham group in the pivotal trial and received the actual procedure, symptom scores improved about 36%, quality of life improved 40%, and urinary flow rate jumped 77% from baseline at two years.¹⁰

One detail that matters for setting expectations: real-world patients tend to be older and start with somewhat less severe symptoms than the carefully selected participants in clinical trials. A multicenter retrospective study confirmed that when baseline symptom severity was matched to trial criteria, outcomes were similar.¹¹ Men starting with milder symptoms may see less absolute improvement simply because there is less room to improve, which is worth discussing with a urologist beforehand.

Sexual Function Preservation

For many men, this is the deciding factor. Traditional prostate surgery carries well-known risks of retrograde ejaculation, where semen flows backward into the bladder during orgasm instead of exiting normally. That happens in the majority of men who undergo conventional transurethral resection. Erectile dysfunction after traditional surgery is less common but remains a concern.

The prostatic urethral lift stands apart here. The randomized controlled trial that specifically evaluated sexual function found no evidence of worsened erectile or ejaculatory function after the procedure. There was no case of new, sustained loss of ejaculation or new erectile dysfunction over the study period. In fact, ejaculatory bother scores improved by about 40% from baseline at one year, and men who entered the study with severe erectile difficulties saw statistically significant improvement in erectile function scores.¹² Longer-term follow-up data confirmed that these sexual function outcomes remained stable through five years.¹³

The reason is anatomical. The procedure does not heat, cut, or remove the tissue surrounding the ejaculatory ducts and the bladder neck sphincter. It simply pins the lobes back. When compared head-to-head against conventional transurethral resection in a randomized trial, the lift group had better erectile and ejaculatory outcomes and no stress incontinence, while about 7% of the conventional surgery group developed some stress incontinence.¹⁴ For younger men, sexually active men, or anyone concerned about fertility, this advantage is substantial and is recognized in current clinical guidance as an important factor in shared decision-making.¹⁵

The Retreatment Question

This is the part of the conversation that gets less airtime in marketing materials but matters a great deal when you are deciding whether to go ahead. The prostatic urethral lift does not stop the prostate from continuing to grow. The implants hold the existing tissue apart, but new growth over years can gradually re-narrow the channel. Some men eventually need a repeat procedure or a different surgery.

A large TriNetX database analysis of over 14,000 initial procedures found a reintervention rate of about 5% at one year, 8% at two years, 11% at three years, and 16% at four years. After the first year, the rate climbed by roughly 3-4 percentage points per year. The most common repeat procedure at one year was another lift, but by four years, conventional transurethral resection had become the most common follow-up surgery.¹⁶

A US healthcare claims study comparing multiple procedures found that at one year, retreatment rates were similar across all major BPH surgeries, hovering around 5-6%. By five years, conventional transurethral resection had the lowest retreatment rate at 7%, while the lift was at about 12%.¹⁷ The same study noted that the lift had the lowest complication rate at one year compared to other surgical options, which helps frame the trade-off: fewer complications upfront, but a higher chance of needing something else down the road.

If retreatment becomes necessary, options remain open. Multiple case series have demonstrated that holmium laser enucleation of the prostate can be performed safely in men who have existing lift implants, though the implants can complicate the procedure. Surgeons have reported that implants may distort the prostate’s anatomy and can jam the morcellator blades used to remove tissue.¹⁸ These are manageable challenges for experienced surgeons, but they are worth factoring in if you are weighing the lift as a bridge procedure with the expectation of eventually moving to something more definitive.

How It Compares to Other Minimally Invasive Options

The most common comparison is with water vapor thermal therapy, which uses steam to destroy excess prostate tissue. Both are office-friendly, minimally invasive, and preserve sexual function. Where they differ is in recovery profile and longer-term durability.

A two-year prospective study found that the lift involved dramatically shorter catheter times (about one day versus 12 days for water vapor therapy) and fewer complications, with about 16% of lift patients experiencing complications compared to about 42% for the steam-based treatment. Water vapor therapy caused more blood in the urine and more urinary tract infections. However, the lift group had a higher reoperation rate.¹⁹ Both procedures produced similar improvements in symptom scores and quality of life over two years.

When followed further out, a multicenter propensity-matched analysis found that reintervention rates diverged over time. At one year, the two were similar (about 3-4% for each). But by five years, the lift’s reintervention rate had climbed to about 11%, compared to about 7% for water vapor therapy, a statistically significant difference.²⁰ The pattern makes biological sense: water vapor therapy destroys tissue, which is permanently removed as the body reabsorbs it, while the lift holds existing tissue aside without eliminating it.

Compared to conventional transurethral resection, the lift offers a faster recovery, fewer sexual side effects, and the ability to avoid general anesthesia. The trade-off is that symptom improvement is generally less robust and retreatment is more likely over time. A randomized trial comparing the two found that while both improved symptoms, the lift produced less impressive symptom score improvement than conventional surgery.¹⁴ Quality of life improvements, however, were similar between the two approaches at two years in another head-to-head study, and only the lift group showed a statistically significant improvement in sleep quality.²¹

Who Is a Good Candidate

The FDA has approved the prostatic urethral lift for prostates up to 100 cubic centimeters in volume, including those with median lobe enlargement. In practice, the guideline recommendations are more conservative. The American Urological Association limits its recommendation to prostates up to 80 cc with lateral lobe disease only, based on the evidence from randomized controlled trials. European guidelines are even tighter, capping the recommendation at 70 cc and excluding median lobes.²²

Despite these guideline limits, there has been extensive real-world use in men with larger prostates and obstructive median lobes. A study specifically evaluating median lobe treatment found that the degree of median lobe protrusion into the bladder did not predict how well men responded, with similar symptom improvements regardless of whether the protrusion was small, moderate, or large.²³ This is encouraging, but it is worth knowing that your urologist may be offering an off-guideline application if your prostate has particular anatomical features.

Men who tend to be the strongest candidates are those with moderate symptoms who want quick relief, a fast return to activity, and who place a high priority on preserving sexual function. Men with very large prostates, severe obstruction, or urinary retention may get better long-term results from more definitive surgical options, even though they come with a tougher recovery.

The Cost Picture

The prostatic urethral lift is not the cheapest option. A cost-effectiveness analysis found it was similar in effectiveness to other minimally invasive therapies but cost more than twice as much as some alternatives.²⁴ A separate analysis found the procedure was more expensive than ongoing medication therapy but also more effective when measured in quality-adjusted life years, making it cost-effective over a five-year horizon at standard willingness-to-pay thresholds.²⁵

Most insurance plans and Medicare cover the procedure when medically indicated. The device cost itself is the main driver of expense; each implant has a substantial price tag, and four to six are typically used per treatment. Men should verify coverage specifics with their insurer, particularly regarding whether the procedure will be performed in a hospital outpatient setting or in a physician’s office, as reimbursement structures differ.

MRI After the Procedure

The stainless steel components of the implants are labeled as MRI-conditional, meaning you can safely have an MRI scan up to 3 Tesla immediately after placement.²⁶ You do not need to wait. This matters because men in the age group most likely to have this procedure are also in the demographic most likely to need prostate MRI for cancer screening or surveillance.

The catch is image quality. While the monofilament suture connecting the two tabs is invisible on MRI, the metal tabs themselves create signal distortion in the surrounding tissue. On standard MRI sequences used for prostate cancer detection, the distortion from the urethral tab is relatively small, with artifacts averaging less than a centimeter in diameter on most sequences. However, on diffusion-weighted imaging, which is one of the key sequences for identifying suspicious lesions, the artifact balloons to nearly three centimeters on average.²⁷ The artifacts are confined to the transition zone, the inner part of the prostate where the implants sit, and do not affect imaging of the peripheral zone where most prostate cancers arise. Specialized artifact-reduction protocols can shrink the distortion somewhat. Still, if you are undergoing active surveillance for a known prostate lesion in the transition zone, this is a conversation to have with both your urologist and radiologist before committing to implants.